Class
Recombinant Human Growth Hormone (rHGH / Somatropin)
Molecular Weight
22,124 Da (191 amino acids)
Half-life
~3–4 hours (subcutaneous)
Purity
≥98% (HPLC/SDS-PAGE)
Form
Lyophilized powder
Storage
Lyophilized: 2–8°C; do NOT freeze once reconstituted
Reconstitution
Bacteriostatic water (1–3 mL)
Mechanism of action
Recombinant somatropin is structurally identical to pituitary-derived human growth hormone (191 amino acids, single chain). It binds the GH receptor causing receptor dimerization and JAK2/STAT5 activation, driving hepatic IGF-1 production and direct tissue effects including protein anabolism, lipolysis, gluconeogenesis, and skeletal/connective tissue growth.
⚠️ For Research Use Only — described exclusively for in vitro and laboratory research by qualified researchers. Not for human or veterinary use. Informational only; does not constitute medical advice or imply efficacy in humans.
Research highlights
IGF-1
Primary driver of hepatic IGF-1 synthesis
Lipolysis
Direct fat mobilization via HSL activation
Anabolic
Protein synthesis and lean mass accretion research
191 AA
Identical to pituitary-derived HGH
Research notes
- IGF-1 production: Primary research target — well-characterized dose-response relationship in animal and human models.
- Body composition: Numerous studies on lean mass accretion and visceral fat reduction over extended protocols.
- GH deficiency models: Extensively studied in adult-onset GHD with documented improvements in body composition and quality of life markers.
- Anti-aging: GH/IGF-1 axis modulation extensively studied in longevity and age-related decline models.
- Wound healing: GH receptor expressed in fibroblasts; accelerated wound repair associated with GH signaling.
